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Abstract
Background: The discovery of disease pathogenesis requires systematic agnostic screening of multiple homeostatic
processes that may become deregulated. We illustrate this principle in the evaluation and diagnosis of a 5-yearold boy with Joubert syndrome type 10 (JBTS10). He carried the OFD1 mutation p.Gln886Lysfs*2 (NM_003611.2:
c.2656del) and manifested features of Joubert syndrome.
Methods: We integrated exome sequencing, MALDI-TOF mass spectrometry analyses of plasma and cultured dermal
fibroblasts glycomes, and full clinical evaluation of the proband. Analyses of cilia formation and lectin staining were
performed by immunofluorescence. Measurement of cellular nucleotide sugar levels was performed with highperformance anion-exchange chromatography with pulsed amperometric detection. Statistical analyses utilized the
Student’s and Fisher’s exact t tests.
Results: Glycome analyses of plasma and cultured dermal fibroblasts identified abnormal N- and O-linked glycosyla‑
tion profiles. These findings replicated in two unrelated males with OFD1 mutations. Cultured fibroblasts from affected
individuals had a defect in ciliogenesis. The proband’s fibroblasts also had an abnormally elevated nuclear sialylation
signature and increased total cellular levels of CMP-sialic acid. Ciliogenesis and each glycosylation anomaly were
rescued by expression of wild-type OFD1.
Conclusions: The rescue of ciliogenesis and glycosylation upon reintroduction of WT OFD1 suggests that both con‑
tribute to the pathogenesis of JBTS10.
Keywords: Joubert syndrome, Ciliopathy, Glycosylation, Molar tooth sign, CMP-sialic acid
Background
Joubert syndrome (JBTS) is a rare genetic condition characterized by hypotonia, developmental delay, cerebellar
dysfunction, a neuroradiologic “molar tooth sign” (MTS),
and variable involvement of other systems [1, 2]. JBTS is
a ciliopathy, and mutations in more than 30 genes encoding products localizing primarily to and around the cilia
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are implicated in its pathogenesis [3, 4]. The genetic
locus associated with JBTS type 10 (OMIM 300804) is
OFD1; mutations in this gene also cause the X-linked
dominant disorder orofaciodigital syndrome I (OFDI,
OMIM 311200), the X-linked recessive disorder Simpson–Golabi–Behmel syndrome, type 2 (SGBS2, OMIM
300209), and an X-linked form of retinitis pigmentosa
(RP23, OMIM 300424) [5].
The ciliary function of the OFD1 protein has not been
fully elucidated, although it does play a role in primary
ciliogenesis and regulation of ciliary length [6, 7]. Loss of
OFD1 in animals causes defects in left/right axis development, ciliogenesis, and neurological development
[8–10]. These phenotypes are consistent with features
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observed in other ciliopathy disorders and reflect the role
of primary cilia in the Shh, Wnt, and planar cell polarity
(PCP) signaling pathways [4]. In the centrosome, OFD1
interacts with lebercilin, a key protein in the pathogenesis of Leber congenital amaurosis [11, 12]. Based upon
its nuclear localization, there is a hypothesis that OFD1
plays a role in chromatin remodeling [13].
The National Institutes of Health Undiagnosed Disease Program (NIH UDP) evaluates individuals with rare
and undiagnosed diseases and an indication of a genetic
etiology. Physicians across multiple specialties consult
on each patient to obtain a full phenotypic description.
In addition to targeted diagnostic tests, the NIH UDP
implements broader, agnostic screens of exome, glycome,
and metabolome.
Herein we report the evaluation of a 5-year-old boy
with Joubert syndrome secondary to mutation in OFD1.
His cultured dermal fibroblasts had impaired ciliogenesis, and his plasma and cultured dermal fibroblasts
had abnormal N- and O-linked glycosylation profiles.
Glycomic evaluation of two unrelated individuals with
JBTS10 detected similar plasma and fibroblast N- and
O-linked glycosylation profiles. Cultured fibroblasts from
the proband also had increased CMP-sialic acid. Overexpression of wild-type OFD1 cDNA rescued both the
glycosylation and ciliary phenotypes. We posit, therefore,
that glycosylation anomalies are a previously undocumented contributor to the pathogenesis of JBTS10.

Methods
Patient enrollment and consent

The proband, UDP-3331, was evaluated in the National
Institutes of Health Undiagnosed Diseases Program (NIH
UDP) and was enrolled in clinical protocol 76-HG-0238,
approved by the NHGRI Institutional Review Board. His
mother, UDP-4786, provided informed consent. NIH-452
was enrolled in protocol “Clinical and Molecular Investigations into Ciliopathies” (Trial NCT00068224); his
legal guardian provided informed consent. Both protocols conform to the 1964 Helsinki Declaration and subsequent amendments standard for patient protection.
Variant identification and Sanger sequencing

Genomic DNA was extracted from peripheral whole
blood of UDP-3331 and UDP-4786 using the Gentra Puregene Blood Kit (Qiagen, Valencia, CA) and
an AutoGen FlexStar with standard procedures. The
DNA of all family members was subjected to an integrated set of genomic analyses including high-density
single-nucleotide polymorphism (SNP) arrays and
whole exome sequencing (WES) as described previously [14–17]. WES was performed on these individuals using the Illumina HiSeq2000 platform and
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the TrueSeqV2 capture kit (Illumina, San Diego, CA).
Sample library preparation, sequencing, and analysis
were performed using the standard NIH Intramural
Sequencing Center (NISC) pipeline [18]. Sequence data
were aligned to human reference genome (hg19) using
Novoalign (Novocraft Technologies, Selangor, Malaysia). To test for copy number variants and to form segregation BED files for exome analysis, Omni Express 12
(hg19) SNP arrays were run on genomic DNA from all
family members as described [14]. Variants listed in the
Variant Call Files (VCFs) were filtered based on rarity,
Mendelian segregation, and predicted deleteriousness
on the Cartagenia platform (Cartagenia N.V., Leuven,
Belgium).
Exome variants were filtered using ExAC release 0.3
population frequency data (MAF < 0.02, 95% confidence interval; homozygote count ≤25) and UDP founders cohort population frequency data (variant allele
count <8). Variants were prioritized based on coding
effect (nonsynonymous, frameshift, stopgain, stoploss,
startloss, inframe), proximity to splice sites (within 20
base pairs of a canonical splice site into the intron, or 5
base pairs into the exon), and CADD v1.3 Phred scores.
Using the Integrative Genome Viewer (https://www.
broadinstitute.org/igv/home), we assessed the quality
of alignment and genotype call of variants. The singlenucleotide deletion identified by exome sequencing was
confirmed using Sanger sequencing of the genomic DNA
from both UDP-3331 and UDP-4786; the forward primer
used was 5′-AGTAGGGTACAGTTCAAGGAGTGG-3′
and the reverse primer was 5′-ATTCTGTGCAGCCTTTCCCAC-3′. DNA amplification was performed
with Platinum Pfx DNA polymerase (ThermoFisher Scientific, Waltham, Massachussets) and standard thermal
cycling protocol with an annealing temperature of 55 °C
for a total of 30 cycles.
OFD1 cloning

Wild-type (WT) cDNA expression constructs were made
by PCR amplification of the OFD1 cDNA sequence from
a sequence-verified TrueORF Gold clone (RC220154,
Origene, Rockville, Maryland). The PCR product was
cloned into pENTR/D-TOPO vector (ThermoFisher Scientific) and subcloned into pLENTI6.3/V5-DEST (ThermoFisher Scientific) using the Gateway LR Clonase II
enzyme (ThermoFisher Scientific). Clones were verified
by Sanger sequencing.
Lentiviral infection and rescue

Lentivirus was generated by transfecting 293FT cells
with the pLENTI6.3-OFD1 construct and the ViraPower
HiPerform Lentiviral Gateway expression kit (ThermoFisher Scientific) as per the manufacturer’s protocol.
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Lentiviral culture supernatant was applied to patient
and adult WT control cells in the presence of polybrene
(10 µg/mL, EMD Millipore, Billerica, Massachusetts).
Stable integration of the OFD1 construct was selected by
addition of 5 µg/mL blasticidin (ThermoFisher Scientific)
to the medium and confirmed by qPCR and immunoblotting. Subsequently, retention of the integrated active
OFD1 construct was selected by growth in medium supplemented with 2.5 µg/mL blasticidin.
Primary fibroblast isolation and culture

Primary dermal fibroblasts from UDP-3331 were derived
from a forearm skin punch biopsy. Additional fibroblast
lines were obtained from ATCC (ATCC-PCS-201-012,
Manassas, Virginia) and Coriell Repository [GM00409
(7 y.o. male) and GM08398 (8 y.o. male), Camden, New
Jersey]. The established fibroblast lines were cultured
in growth medium, consisting of Dulbecco’s Modified
Eagle Medium (DMEM) with 1 g/L glucose (low glucose
DMEM), 10% heat inactivated fetal bovine serum (HI
FBS, ThermoFisher Scientific), and 1% antibiotic/antimycotic (ThermoFisher Scientific). Culture of primary
fibroblasts for glycome analysis utilized α-MEM (Cellgro,
Mediatech, Manassas, Virginia) supplemented with 15%
HI FBS and 1% antibiotic/antimycotic for 24–48 h prior
to cell harvest.
RNA isolation and qRT‑PCR analysis

RNA extraction from cultured dermal fibroblasts was
performed as per the manufacturer’s protocol using the
Qiagen RNeasy Mini kit (Qiagen, Hilden, Germany)
with on-column DNA digestion. Equal amounts of
RNA were reverse-transcribed from each cell line using
the OmniScript cDNA first-strand synthesis kit (Qiagen). SYBR Green reagent (Qiagen) was used to amplify
OFD1 and GAPDH for a ∆∆Ct relative quantification of OFD1 expression on an ABI7500 Fast RealTime
PCR machine with the Melt Curve option. Quantification and quality control parameters were according to
the standard manufacturer’s settings. Primers used for
OFD1 were 5′-CGGAGCAGAAAGTGGGTCTTT-3′
and 5′-TGGCATGTTCCCTGCAGATT-3′; primers for
GAPDH were 5′-TGCACCACCAACTGCTTAGC-3′ and
5′-GGCATGGACTGTGGTCATGAG-3′.
Immunoblotting

Fibroblasts were cultured to near 100% confluence,
rinsed twice with PBS, and harvested by in-dish lysis with
RIPA buffer (Sigma-Aldrich, St. Louis, Missouri) supplemented with 1× complete Ultra Protease Inhibitor Cocktail (Sigma-Aldrich). Total protein concentration of the
lysates was determined using the DC Protein Assay (BioRad, Hercules, California) and equal amounts of protein
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were run for each sample on SDS-PAGE gels (4–12%
gradient, BioRad) in SDS–Tris–glycine buffer. Proteins
were transferred using a standard wet-transfer method to
Immobilon-FL PVDF membranes in Tris–glycine buffer
with 20% methanol. Blocking was performed with Odyssey blocking buffer in PBS (LiCor, Lincoln, Nebraska);
primary antibodies were incubated overnight at 4 °C in
fresh blocking solution. Membranes were washed three
times with PBS-Tween 20 (0.1%) and incubated with
Odyssey near-IR conjugated secondary antibodies for
1 h in Odyssey blocking buffer with Tween-20 (0.1%) and
SDS (0.2%). Prior to imaging on a LiCor Odyssey CLx,
membranes were washed three times with PBS-Tween
20 and rinsed once with diH2O. Band quantification and
analysis were performed using the CLx imaging software (LiCor). Antibodies used were anti-OFD1 (1:1000,
TA308968, Origene), anti-α-tubulin (1:5000, ab7291,
Abcam; Cambridge, Massachusetts), anti-rabbit IR800
(1:10,000, 925–32,211, LiCor), and anti-mouse IR680
(1:10,000, 925–68,020, LiCor).
Immunofluorescence of cultured fibroblasts

Staining of cultured fibroblasts, either with antibodies
or lectins, utilized a similar protocol with minor variations detailed below. Cultured cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS)
at room temperature for 10 min, or in ice-cold 100%
methanol at −20 °C for 15 min, or a combination of both.
The fixed cells were washed three times with PBS. Paraformaldehyde-fixed cells were permeabilized with 0.5%
NP-40 detergent in PBS at room temperature for 10 min
then washed three times in PBS. The fixed and permeabilized cells were then incubated with a blocking buffer
for 1 h. Primary staining reagent(s) were diluted in blocking buffer and applied for 1–2 h at room temperature or
overnight at 4 °C. The cells were then washed with PBS
three times. The cells were then incubated with secondary detection reagents with fluorophore conjugates
diluted in blocking buffer for 1 h at room temperature.
After washing the cells three times with PBS, the coverslips were mounted onto slides with the indicated mounting media prior to imaging.
OFD1 localization and cell morphology analysis

Cells were grown on 12-mm round coverslips to 50–70%
confluence at the time of fixation. Cells were fixed either
in paraformaldehyde or methanol, depending upon manufacturers’ recommendations for the primary antibodies.
The blocking reagent used was 4% BSA (bovine serum
albumin) in PBS, and the primary antibodies used were
OFD1 (1:100, Origene), ɣ-Tubulin (1:1000; T5326, SigmaAldrich), α-tubulin (1:2000, ab7291, Abcam), PCM1
(1:100, sc-50164, SantaCruz Biotechnology, Dallas,
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Texas), GM-130 (1:250, 610822, BD Biosciences, San
Jose, California), TGN-46 (1:200, GTX74290, Genetex,
Irvine, California), or KDEL (1:100, ab12223, Abcam).
Alexa Fluor conjugated secondary antibodies used were
Alexa488 Donkey anti-Rabbit, Alexa555 Donkey antiMouse, and Alexa647 Donkey anti-Rabbit (ThermoFisher
Scientific). Where indicated, DNA was counterstained
with Hoechst 33342 (ThermoFisher Scientific) and coverslips were rinsed with PBS. The mounting medium
was ProLong Gold antifade mounting medium (ThermoFisher Scientific) and the slides were imaged using a
20× or 40× objective on a Zeiss LSM 700 confocal laserscanning microscope (Carl Zeiss Microscopy, GmbH,
Jena, Germany).

were seeded at 0.5 × 105 per 12-mm round coverslip and
cultured overnight. The cells were fixed with paraformaldehyde or methanol as indicated in the text. Blocking
was performed with 4% BSA in PBS, followed by primary incubation with MAL II, SNA, and/or PNA lectins
(20 µg/mL). Detection of biotinylated MAL II required
secondary incubation with Streptavidin AlexaFluor 350
(S-11,249, ThermoFisher Scientific). In cells without
MAL II staining, DNA was stained with Hoechst 33342
(ThermoFisher Scientific). Coverslips were mounted on
slides using ProLong Gold anti-fade reagent then imaged
using a 20× objective on a Zeiss LSM 700 confocal laserscanning microscope. Image analysis was performed
using ImageJ software [19].

Cilia measurements

Neuraminidase treatment and cilia measurement

Fibroblasts were grown to 80% confluence and then
serum starved for 48 h. Cells were fixed with 4% paraformaldehyde for 5 min at room temperature followed
by ice-cold methanol for 4 min at −20 °C. The blocking buffer used was PBS containing 10% normal donkey
serum, 1% BSA, and 0.1% triton X-100 for 1 h. Fixed
cells were incubated overnight with primary antibodies
(1:1000–1:2000, mouse anti-acetylated Tubulin, T6793,
SigmaAldrich; 1:200, goat anti-γ tubulin, sc-7396, Santa
Cruz). Secondary antibodies used were AlexaFluor
conjugated secondary antibodies (Life Technologies).
Coverslips were mounted using Fluoromount G with
4′,6-diamidino-2-phenylindole (DAPI) (Southern Biotech, 0100-20, Birmingham, Alabama).
Fourteen image z-stacks with 0.3 mm spacing were
taken with a CoolSNAP HQ2 digital monochrome camera (Photometrics, Tucson, Arizona, USA) through a
Marianas live cell imaging system (Intelligent Imaging Innovations, Denver, Colorado, USA) using a Plan
Apochromat 63X, 1.4 NA oil objective.
Percentage of ciliated cells and length measurements
were made in FIJI on 16-bit sum projection images of
z-stacks. Cilia were defined as linear acetylated tubulinpositive structures >1-μm long with a punctate gammatubulin signal at one end. The percentage of ciliated
cells was determined by dividing the number of ciliated
cells by the number of DAPI-positive nuclei in the same
images. To measure cilium length, we manually painted
a mask over each cilium (defined by acetylated tubulin)
with a 3 pixel-wide brush, skeletonized the cilium mask,
and applied the maximum branch length function.

Adult WT fibroblasts were plated directly on coverslips
at 0.5 × 105 cells per 12-mm coverslip density, allowed
to adhere overnight, and then grown for additional 48 h
in the absence of serum. Half of the coverslips were
washed with Hank’s Balanced Salt Solution (HBSS) and
then incubated for 1 h at 37 °C in 1 mU/mL neuraminidase (Sigma, N2133) dissolved in HBSS. Untreated cells
were left in serum-free media. Cells were subsequently
washed three times in PBS and then fixed using ice-cold
methanol. Staining for cilia utilized anti-ARL13B (1:250,
ProteinTech, Rosemont, Illinois) and anti-gamma tubulin
(1:250, Sigma-Alridch) with Hoechst 33342 DNA counterstaining. DNA counterstaining in conjunction with
lectin staining, which was performed as stated above, utilized the far-red dye DRAQ5 (Abcam). Cilia were defined
as above and measured with FIJI software; the percentage
of ciliated cells was defined as above.

Lectin staining of cultured fibroblasts

Biotinylated Maackia amurensis lectin II (MAL II), fluorescein Sambucus nigra (elderberry) bark lectin (SNA),
and rhodamine Peanut Agglutinin (PNA) were obtained
from Vector Laboratories (Burlingame, California). Cells

Glycome analysis

Primary dermal fibroblasts were cultured and processed
to release N- and O-linked glycans as previously reported
[20]. Fibroblasts were cultured in DMEM with 10% HI
FBS and 1% antibiotic/antimycotic to 80% confluence
in a 15-cm culture disk. After one rinse with PBS, the
medium was changed to α-MEM containing 1000 mg/L
d-glucose, 15% HI FBS, and 1% antibiotic–antimycotic.
Upon reaching 100% confluence, the cells were washed
twice with PBS then harvested using a cell scraper. The
cells were then pelleted in PBS by centrifugation. Fibroblast pellets were lysed in 300 µL PBS with sonication and
400 µg of total glycoprotein was collected from the cell
lysate. Free glycans were removed by Ultracel-10k Centrifugal filter (EMD Millipore, Billerica, Massachusetts)
and the enriched glycoproteins were divided into 200-µg
aliquots for N-glycan and O-glycan preparation. N-linked
glycans were released from 200 µg of total glycoproteins
or 10-µL plasma samples using PNGase F digestion (New
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England Biolabs, Ipswich, Massachusetts, USA). The
released N-linked glycans from plasma or cells were purified and desalted by solid-phase extraction using a SepPak C18 and carbograph column. O-linked glycans were
released using β-elimination with sodium borohydride.
O-linked glycans from plasma or cells were purified and
desalted using an AG 50 W-X8 resin cation exchange
column. N-linked glycans or O-linked glycans were permethylated with sodium hydroxide and iodomethane
in dimethyl sulfoxide (DMSO) as described before [21].
Following permethylation, glycans were extracted with
water/chloroform (2:1, vol/vol) for four times and dried.
Samples were then dissolved in 50% methanol, spotted
with 11% 2,5-dihydroxylbenzoic acid matrix (1:1 vol/vol),
and measured by MALDI-TOF using the positive mode
on Ultraflex MALDI-TOF/TOF system (BrunkerDaltonics, Billerica, Massachusetts).
Nucleotide sugar analysis

Fibroblasts were cultured in growth medium in 15-cm
culture disks until 90–100% confluent, rinsed with PBS
and harvested by scraping into PBS. Cells were counted
using an automated cell counter (BioRad TC20) and
pelleted at 500 RCF for 5 min. Nucleotide sugars were
extracted based on previously published methods [22,
23]. Briefly, cell pellets were lysed in 70% ethanol, 300 µL
of ethanol per million cells, and subjected to three
rounds of sonication for 5 s at 15% amplitude. An aliquot of lysate was taken for total protein quantification.
Lysates were pelleted at 16,000×g for 10 min at 4 °C and
the supernatant was collected and lyophilized. The lyophilized supernatant was resuspended in 40 mM sodium
phosphate buffer (pH 9.2) at 60 µL per million cells and
further diluted based on total protein from the initial
lysate relative to adult WT. The supernatant was applied
to a Millipore spin column (10kD MW cut off ) and spun
for 30 min at 16,000×g. The extracted nucleotide sugars were analyzed by high-performance anion-exchange
chromatography with pulsed amperometric detection
(HPAEC-PAD) on a Dionex instrument as previously
reported [22] and were quantified by comparison to a
standard curve of dilutions of CMP-sialic acid (C8271,
Sigma-Aldrich) in 40 mM sodium phosphate.

Results
Clinical report

The proband, UDP-3331, is a 5-year-old male, born
to unaffected parents; he had an unaffected sister. At
14 months, he presented with severe feeding problems
requiring placement of a G-tube. At 18 months, he was
evaluated for hypotonia and dysmorphia. Over the next
4 years, his documented features included oral motor
dysfunction, sleep apnea, myopathy, developmental
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delay, easy bruising, hypertrichosis, rocker bottom feet,
and dysmorphic facial features, including a notched
upper lip and submucous cleft palate. Following 5 years
of non-diagnostic evaluations, the proband was evaluated
at the NIH UDP. His brain MRI revealed a molar tooth
sign (Fig. 1a) that, combined with his clinical features
(Table 1), suggested a diagnosis of Joubert syndrome.
Exome sequencing identifies an OFD1 mutation

Analysis of exome sequence data for variants in
genes associated with Joubert syndrome revealed
NM_003611.2: c.2656del, a maternally inherited hemizygous mutation in OFD1. Sanger sequencing confirmed
the variant in the proband and mother (UDP-3331 and
UDP-4786, respectively; Fig. 1b) and refined the diagnosis to JBTS10. Considering the apparently normal phenotype of the mother, no further testing or analysis of
samples from individual UDP-4786 was performed.
The OFD1 mutant protein is stable and appropriately
localized

NM_003611.2: c.2656del, which occurred in the 20th
exon, is predicted to encode a frameshift leading to a
premature stop codon, p.Gln886Lysfs*2. To test if this
mutation caused nonsense-mediated mRNA decay and
thereby loss of OFD1 function, we measured OFD1
mRNA levels in cultured dermal fibroblasts by qRT-PCR.
Following normalization to GAPDH mRNA abundance,
the UDP-3331 OFD1 mRNA levels were approximately
30% of those in control dermal fibroblasts (Fig. 1c), a
finding consistent with loss of function and previous
reports [11]. OFD1 protein levels, as measured by immunoblotting, were approximately 50% of those in control
dermal fibroblasts following normalization to α-tubulin
(Fig. 1d). Lentiviral transduction of a WT copy of OFD1
cDNA into the dermal fibroblasts of UDP-3331 partially
rescued OFD1 mRNA and protein expression (Fig. 1c, d).
We next determined the intracellular localization of
the residual OFD1 protein by immunofluorescent studies of dermal fibroblasts. In both UDP-3331 and control,
residual OFD1 localized with the centrosome as judged
by co-localization with centrosome markers ɣ-tubulin
and PCM1 (Fig. 2a). Notably, in both affected and control fibroblasts, we observed variable co-localization of
all three centrosomal proteins; the variability is likely
due to the presence of non-centrosomal aggregates of
PCM1 [24] and cell-cycle differences among the population of cells resulting in variable ɣ-tubulin localization
to the centrosome [25, 26]. Microtubule morphology
(α-tubulin) appeared to be unaffected in the JBTS10 cell
line as compared to control (Fig. 2b).
Given the role of the basal body and microtubules in
regulating trafficking through the secretory pathway, we
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Fig. 1 Clinical and molecular evidence for Joubert syndrome type 10 diagnosis. a Magnetic resonance imaging of the proband, UDP-3331, reveals
the hallmark “molar tooth sign” of the superior cerebellar peduncles (arrow). b Sanger sequencing of both the proband, UDP-3331, and his mother,
UDP-4786, confirms an OFD1 single-nucleotide deletion (c.2656del) in the proband and maternal inheritance. c Analysis of mRNA transcripts from
adult control cells (“WT”), UDP-3331, and UDP-3331 + OFD1 rescue shows reduced mRNA levels in the proband. Error bars represent standard error
of four replicates; data are normalized to GAPDH expression and plotted relative to WT OFD1 expression levels. Asterisk indicates p < 0.001 for twotailed, heteroscedastic Student’s t test. d Western blot analysis of OFD1 levels in UDP-3331, UDP-3331 + OFD1 and adult WT primary fibroblast lines;
one representative blot with OFD1 and α-tubulin is shown in the top panels; average of 3 replicate blots with independent lysates is shown in the
lower panel. OFD1 levels are normalized to α-tubulin and plotted relative to WT OFD1 protein levels

also examined the structure of these compartments in
the affected cells [27]. As judged by immunofluorescence,
there was no change in the morphology of the endoplasmic reticulum and the cis- and trans-Golgi of UDP-3331
compared to control adult dermal fibroblasts (Fig. 2c, d).
Decreased cilium number in OFD1 p.Gln886Lysfs*2 mutant
cells

The above observations raised the question as to whether
the remaining OFD1 protein that localized to the centrosome in UDP-3331 dermal fibroblasts was sufficient
to support ciliogenesis. Comparable to a fetal-affected
JBTS10 cell line (UW172-4, NM_003611.2: c.277G > T,
p.Val93Phe [28]), UDP-3331 dermal fibroblasts showed a
decreased ability to form cilia that was rescued to near
WT levels by expression of WT OFD1 (Fig. 3a, b). Thus,
consistent with previous studies [8], the reduction in
OFD1 mRNA and protein levels in UDP-3331 dermal
fibroblasts is sufficient to impede cilia formation.

JBTS10 tissues have OFD1‑dependent anomalies of protein
glycosylation

Evaluation of UDP-3331 included a screen for anomalies
of N- and O-linked glycans in plasma and of free oligosaccharides in urine. This detected a decrease in mature,
fully sialylated and galactosylated N-linked glycans at m/z
2973 (Table 2), whereas monosialo glycan at m/z 2431
and monosialo, monogalacto glycan at m/z 2227 were
increased. In plasma O-linked glycans sialylated T antigen (see Additional file 1: Table S1) was decreased, and
T antigen was at the low end of the normal range. Both
the plasma N- and O- glycosylation profiles indicated an
abnormality in sialic acid utilization in the trans-Golgi or
abnormal metabolism of sialic acids (see Additional file 2:
Figure S1). Urinary oligosaccharides were within the normal range. Supporting the association of glycosylation
anomalies with JBTS10, similar plasma N-linked findings
were detected in another individual with JBTS10 (NIH452, NM_003611.2: c.149A>G [29, 30], Table 2); O-linked
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Table 1 Phenotype of JBTS10 patients
Joubert syndrome phenotypes (JBST1; OMIM: 213,300)
Head and neck
Face

Macrocephaly
Prominent forehead
High, rounded eyebrows
Hemifacial spasms
Low-set ears
‘Tilted’ ears

Eyes

Abnormal, jerky eye movements
Impaired smooth pursuit
Impaired saccades
Oculomotor apraxia
Coloboma of optic nerve
Chorioretinal coloboma
Epicanthal folds
Ptosis

Nose

Upturned nose
Anteverted nostrils

Mouth

Triangular-shaped open mouth
Protruding tongue
Rhythmic tongue movements

Respiratory

Neonatal breathing dysregulation
Hyperpnea, episodic
Tachypnea, episodic
Central apnea

Liver
Central nervous system

Hepatic fibrosis (less common)
Delayed psychomotor development
Mental retardation/intellectual disability
Ataxia
Hypotonia
Occipital meningocele (less common)
Hypoplasia of the brainstem
Malformation of brainstem structures
‘Molar tooth sign’ on MRI
Cerebellar vermis hypoplasia
Dysgenesis or agenesis of the cerebellar vermis
Deep posterior interpeduncular fossa
Thick and elongated superior cerebellar peduncles

Behavioral psychiatric manifestations

Hyperactivity
Aggressiveness
Self-mutilation

Additional phenotypes

Submucosal cleft palate
Notched upper lip or tongue
Oral motor dysfunction
Recurrent aspiration pneumonia
Easy bruising
Rockerbottom feet
Hypertricosis
Moderate hearing loss
Double hair whorl
GI tube placed in infancy

UDP-3331
+

−

−

−

+

−

−

+

+

+

−

−

+

−

+

NIH-452
+

+

+

−

+

−

+

+

+

+

−

−

−

+

+

−

+

−

+

+

−

+

−

−

+

−

+

+

−

+

+

−

+

+

+

+

+

+

−

−

+

+

+

+

+

+

+

+

+

+

+

+

−

+

+

+

+

+

+

+

+

+

−

−

+

+

+

+

+

+

−

−

+

−

+

+

−

−

−

−

−

−

+
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Table 1 continued
Joubert syndrome phenotypes (JBST1; OMIM: 213,300)

UDP-3331

GER (gastroesophageal reflux)
Telecanthus

+

+

Eczema

+

Hip dysplasia

−

Micropenis

−

Pectus excavatum

−

Growth retardation
Elbow dislocation, chronic

−

−

NIH-452
+

+

−

+

+

+

+

+

Comparison of the standard Joubert syndrome features with those reported for UDP-3331 and NIH-452. Additional features noted in the patients are listed

glycosylation was not tested in this individual due to limited sample amount.
To exclude the possibility that these findings were nonspecific, we defined the N- and O-linked glycome profile in cultured dermal fibroblasts from JBTS10 patients
UDP-3331 and UW172-4. Both cell lines had increased
levels of mono-sialylated N-glycan species compared to
controls (Table 3). Both cell lines also had abnormal formation of core 2 mature, sialylated O-linked glycans (see
Additional file 3: Table S2) and thus a relative high abundance of the core 1 species. Core 1 sialylated T antigen
from cellular protein was not reduced. Each N-glycosylation abnormality in the cultured JBTS10 dermal fibroblasts was partially rescued by expression of WT OFD1
(Table 3, UDP-3331 + OFD1). As was observed for the
plasma results in Table 2, we observed a defect in sialylated glycans in JBTS10 patient fibroblast samples.
Cultured JBTS10 dermal fibroblasts have increased nuclear
CMP‑sialic acid

To characterize further the glycomic profile abnormalities, we performed lectin immunofluorescence using
SNA, which preferentially binds to α-2,6-linked sialic
acids, and MALII, which primarily binds α-2,3-linked
sialic acids. We observed increased nuclear localization
of the SNA fluorescently labeled lectin signal in both of
the JBTS10 dermal fibroblast lines, and this was reduced
upon rescue with WT OFD1 (Fig. 4a, b, p < 0.05).
Given that the increased nuclear SNA signal was only
observed in JBTS10 cells fixed with paraformaldehyde
but not with methanol (Fig. 4c), we hypothesized that
the SNA-reactive epitope was a small molecule, lipid,
or protein not preserved by methanol fixation. Unlike
other nucleotide sugars, which are synthesized in the
cytosol, CMP-sialic acid (CMP-SA) is synthesized in the
nucleus and, under aldehyde fixation, could constitute
a small SNA-reactive epitope [31]. Using HPAEC-PAD,
comparison of nucleotide sugars levels between UDP3331 and adult WT cultured dermal fibroblasts showed
a 39% increase in CMP-SA in UDP-3331 (Fig. 5a, b);

introduction of WT OFD1 decreased the CMP-SA levels
by 50% (p < 0.005, unpaired t test).
Neuraminidase treatment destabilizes cellular primary cilia

Given the association between abnormal sialylation and
ciliogenesis in the JBTS10 patient lines, we sought to
examine the effects of disrupting sialylation on cilia stability in control cells. Following growth in ciliogenic conditions, WT cells were either left untreated or treated
with neuraminidase to remove sialic acids from the cellular glycoproteome. The neuraminidase used is isolated
from Clostridium perfringens and can cleave α-2,3-,
α-2,6-, or α-2,8-linked sialic acids, although it has highest affinity for α-2,3-linkages. Cells were then fixed and
stained for cilia markers and cilia were measured. We
observed a significant decrease (p < 0.001) in average cilia
length in WT cells following neuraminidase treatment
and a modest (p < 0.05) decrease in the number of ciliated cells in the population (Fig. 6a–d). Neuraminidase
treatment successfully disrupted glycoprotein sialylation
as indicated by increased lectin staining with PNA, which
strongly binds galactose epitopes normally masked by
terminal sialic acids (Fig. 6e). Additionally, in the absence
of neuraminidase treatment, we observed co-localization of SNA-reactive epitopes with the cilium marker
ARL13B, indicating that some proteins localized to the
primary cilia are sialylated (Fig. 6f ).

Discussion
Herein we have detailed the clinical and molecular phenotypes of a boy, UDP-3331, with Joubert syndrome type
10 (JBTS10). His clinical, molecular, and cellular findings
are consistent with other reports of JBTS10. Interestingly,
we observed a global alteration in the N- and O-linked
glycosylation profiles of three JBTS10 patients. The most
pronounced and consistent glycosylation change was
a decrease of mature, fully sialylated N-glycans and an
increase in total cellular CMP-sialic acid. Within cultured skin fibroblasts, lentiviral rescue with WT OFD1
cDNA normalized the abnormal glycosylation profiles in
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Fig. 2 Cellular morphology and analysis of JBTS10 skin fibroblasts. a Co-localization analysis of OFD1 (magenta) signals in proband, proband
rescued, and adult WT cells with ɣ-tubulin (red) and PCM1 (green). Inset higher magnification of the region outlined with dotted lines. b Immunofluo‑
rescence staining for OFD1 (green) and α-tubulin (red) in fibroblasts of the proband (UDP-3331), proband rescued (UDP-3331 + OFD1), and adult
WT control. c Comparison of endoplasmic reticulum structure (KDEL, green) in UDP-3331 and WT cells. d Comparison of the cis- (GM-130, green) and
trans- (TGN-46, red) Golgi in UDP-3331 and WT cells. DNA was stained with Hoechst 33,342 (blue). All scale bars represent 20 µm

Kane et al. Cilia (2017) 6:2

Fig. 3 Analysis of ciliogenesis in JBTS10 and control skin fibro‑
blasts. a The percentage of ciliated cells following 48 h of serum
starvation in UDP-3331, UDP-3331 + OFD1 rescue, adult WT, adult
WT + OFD1 overexpression, UW172-4, and fetal WT control cells. Error
bars represent the 95% confidence interval for the average of three
independent experiments. Asterisks indicate p < 0.001, Student’s t
test. b Representative images of ciliated cells for the indicated cell
lines. Acetylated tubulin (red) and ɣ-tubulin (green) mark the cilia and
basal body, respectively. DNA was stained with DAPI (blue). Scale bars
10 µm

JBTS10 patient cells and the ciliogenesis phenotype previously associated with OFD1 mutations.
The observed decrease in primary cilia stability following neuraminidase removal of sialic acids from the
glycoproteome and the co-localization of sialylated glycoproteins with the primary cilium suggest that protein
sialylation plays a role in ciliary homeostasis. We hypothesize, therefore, that the abnormal glycosylation might
contribute to the ciliogensis defect. Two factors, however,
remain to be addressed. First, our glycomic studies on
primary dermal fibroblasts were performed under growth
conditions that do not promote ciliogenesis, and therefore, it is unclear how much of the abnormal glycosylation is attributable to ciliary proteins. Second, because of
technical limitations to performing glycome profiling on
the cilia, we are unable to assess biochemically whether
the ciliary proteome is aberrantly glycosylated in patient
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cells. These two limitations provide testable hypotheses
for future investigations.
Regardless of the impact directly on the ciliary proteins, the accumulation of the sialic acid epitope that
binds to the lectin SNA in the nuclei of JBTS10 patient
cells and the increased CMP-SA and the accumulation
of incompletely sialylated N-glycans are consistent with
a defect in CMP-SA metabolism or transport. Unlike
other nucleotide sugars, CMP-SA is synthesized in the
nucleus, rather than the cytosol; thus, CMP-SA must
be transported through two distinct membrane-bound
organelles for proper sialylation to occur [32, 33]. There
are many possible ways in which alterations in levels of
functional OFD1 could lead to changes in sialylated glycoproteins. First, nuclear OFD1 [13] might contribute
to CMP-SA metabolism. Second, defects of ciliogenesis
might alter cell signaling [34–36] or the role of the basal
body in regulating microtubules and intracellular transport to impair CMP-SA transport from the nucleus and
subsequent utilization in the Golgi. Disruption of the
centrosome structure and tethering of the daughter centrioles are associated with abnormal Golgi structure [37],
and alterations in the structure of the Golgi cisternae
would undoubtedly influence the glycosylation enzymes
that are targeted specifically to cis- or trans-Golgi compartments [38]. However, we did not observe any obvious
changes in centriole separation or Golgi structure. Third,
the increased sialylation of O-linked core 1 T antigen on
cellular proteins and the decreased sialylation of O-linked
core 1 T antigen on secreted glycoproteins in plasma
might suggest altered exocytosis and endocytosis of glycoproteins. Finally, elevated processing of sialoglycoproteins or enhanced turnover of surface sialoglycoproteins
might contribute to the abnormal glycosylation signature observed [39]. Each of these potential mechanisms
highlights the important role of ciliary and basal body
proteins in cell physiology and the delicate homeostatic
balance that can be indirectly disrupted by single-gene
mutations.
Prior associations between primary ciliopathies and
altered glycosylation have been limited to observations of
the mutated ciliary proteins. Polycystin-2, polycystin-1,
and aquaporin-11 mutations associate with abnormal
glycosylation of ciliary proteins [40–42]. Changes in protein trafficking, which result in altered protein glycosylation, have been linked to polycystic liver disease [43].
There exists corroborating evidence that altered glycosylation might contribute to the pathogenesis of some
ciliopathies. Primary defects in glycosylation, collectively
referred to as Congenital Disorders of Glycosylation
(CDGs), cause phenotypes similar to those of primary ciliopathies and disrupt cilia function. Defects in the N-linked
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Table 2 Summary of N-glycan profiles of JBTS10 patient plasma
Centroid
mass (m/z)

Predicted glycan
species

UDP-3331
(% total glycans)

NIH-452
(% total glycans)

Ref low
(% total glycans)

Ref high
(% total glycans)

1580.2

Hex5 HexNAc2

0.69

0.91

0.23

1.88

1662.3

Hex3 HexNAc4

0.03

0.00

0.00

0.22

1784.4

Hex6 HexNAc2

0.51

0.48

0.00

0.87

1866.5

Hex4 HexNAc4

0.19

0.00

0.06

0.53

1982.5

Hex4 NeuAc1 HexNAc3

0.48

0.43

0.08

0.80

1988.5

Hex7 HexNAc2

0.19

0.00

0.00

0.39

2070.6

Hex5 HexNAc4

–

0.15

0.00

0.30

2156.7#

Hex4 dHex1 HexNAc3
NeuAc1

0.05

0.00

0.06

0.17

2186.7

Hex4 dHex1 NeuGc1
HexNAc3

–

0.39

0.00

0.89

2192.7

Hex8 HexNAc2

0.32

0.00

0.06

0.61

2227.7^

Hex4 HexNAc4 NeuAc1

1.38

1.54

0.40

1.28

2285.2^

Hex4 dHex1 HexNAc5

0.17

–

0.00

0.16

2431.9^

Hex5 HexNAc4 NeuAc1

5.87

9.88

2.38

6.74

2606.0

Hex5 dHex1 HexNAc4
NeuAc1

0.54

1.87

0.79

2.87

2793.3†

Hex5 HexNAc4 NeuAc2

20.29

40.58

28.38

58.23

2966.5

Hex5 dHex1 HexNAc4
NeuAc2

1.49

2.89

2.49

3.36

3241.6

Hex6 HexNAc5 NeuAc2

1.13

1.52

0.08

1.70

3415.6

Hex6 dHex1 HexNAc5
NeuAc2

0.25

0.00

0.00

0.87

3602.9

Hex6 HexNAc5 NeuAc3

3.31

6.72

1.64

6.10

3776.6#

Hex6 dHex1 HexNAc5
NeuAc3

0.94

0.38

0.00

7.27

The percentages of total glycans for the indicated N-glycan species in the plasma of UDP-3331 and NIH-452 are shown along with reference (Ref ) range derived from
controls. Species with values in the low-normal range in the JBTS10 samples are flagged with a pound sign (#). Species below the normal range in JBTS10 sample(s)
are flagged with a dagger (†). Species that are elevated above the normal range are flagged with a caret (^)
#

Low normal in JBST10

^

Above normal in JBST10

†

Below normal in JBST10

glycosylation genes ALG3, ALG8, and ALG9, as well as the
O-linked glycosylation gene B3GALTL, variably result in
polycystic kidneys, cleft lip or palate, polycystic ovaries,
and abnormal development of the brain including the corpus callosum [44–47]. Mutations in GALNT11, encoding
polypeptide N-acetylgalactosaminyltransferase, cause ciliary dysfunction and heterotaxy [48].
The importance of glycosylation in neural development
is well illustrated by animal models of disrupted glycosylation. A knock-out of the only sialyltransferase gene
in D. melanogaster caused significant neurological symptoms, implicating sialylation as a key factor in neurodevelopment and function [49]. Additionally, disruption
of proteoglycan formation in C. elegans by alteration of
microRNA levels causes aberrant migration of neurons

[50]. Alterations of polysialic acid epitope formation in
mice also cause abnormal neuronal development and
disrupted neuron migration, likely due to changes in sialylation of NCAM [51]. The cerebellum and midbrain
anomalies that result in the molar tooth sign (MTS) are
thought to arise due to aberrant migration of neurons in
the cerebellum. Given that both N- and O-linked CDGs
present with abnormal development of other brain structures, and animal models with altered sialylation show
distinct neurodevelopment defects, it is possible that the
altered glycosylation we observe in JBTS10 patients may
contribute to the formation of MTS. Recent work by Feng
and colleagues to identify the N-glycoproteome in the
mouse brain revealed that several key proteins for brain
development are N-glycosylated [52].
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Table 3 Summary of N-glycan profiles of JBTS10 patient fibroblasts
Centroid
mass (m/z)

Glycan structure

UDP-3331 (%
total glycans)

UDP-3331
UW172–4 (%
+OFD1 (% total total glycans)
glycans)

Adult control (% Ref low (% total Ref high (% total
total glycans)
glycans)
glycans)

1171.9

Hex3 HexNAc2

4.09

7.07

1.63

5.00

0.23

12.38

1346.0

Hex3 dHex1
HexNAc2

3.86

5.28

1.06

5.09

0.00

6.11

1417.1#

Hex3 HexNAc3

0.00

0.79

0.00

0.78

0.00

0.78

1580.2

Hex5 HexNAc2

8.19

11.68

4.55

8.46

1.83

14.29

1621.3

Hex4 HexNAc3

0.56

0.76

0.00

0.98

0.00

0.98

1662.3

Hex3 HexNAc4

0.00

0.00

0.00

0.00

0.00

0.29

1784.4

Hex6 HexNAc2

19.88

17.97

15.17

18.31

6.54

20.74

1825.4

Hex5 HexNAc3

0.57

0.62

0.00

0.90

0.00

0.90

1866.5

Hex4 HexNAc4

0.74

0.81

0.00

0.66

0.00

0.70

1982.5

Hex4 NeuAc1
HexNAc3

0.00

0.00

0.00

0.00

0.00

0.30

1988.5

Hex7 HexNAc2

9.81

9.62

12.04

9.67

4.87

14.86

2029.6

Hex6 HexNAc3

0.54

0.52

0.00

0.93

0.00

2.19

2070.6

Hex5 HexNAc4

4.39

4.03

2.03

3.20

0.00

3.88

2156.7#

Hex4 dHex1
HexNAc3
NeuAc1

0.00

0.34

0.00

0.52

0.00

0.75

2192.7

Hex8 HexNAc2

16.18

13.96

27.66

16.04

0.00

32.90

2227.7

Hex4 HexNAc4
NeuAc1

0.00

0.00

0.00

0.00

0.00

0.20

2396.9

Hex9 HexNAc2

9.28

7.49

18.11

9.09

0.24

32.34

2431.9^

Hex5 HexNAc4
NeuAc1

2.18

1.47

2.92

1.83

0.00

1.83

2606.0^

Hex5 dHex1
HexNAc4
NeuAc1

6.85

4.19

2.23

4.70

0.00

4.70

2793.3

Hex5 HexNAc4
NeuAc2

0.86

0.45

1.53

1.00

1.21

6.80

2967.3

Hex5 dHex1
HexNAc4
NeuAc2

2.69

1.45

4.74

2.02

3.38

10.79

3241.6

Hex6 HexNAc5
NeuAc2

0.00

0.00

0.00

0.17

0.00

1.96

3415.6

Hex6 dHex1
HexNAc5
NeuAc2

0.45

0.22

0.84

0.39

0.43

5.84

3602.9†

Hex6 HexNAc5
NeuAc3

0.33

0.00

0.00

0.28

0.64

23.23

3776.6#

Hex6 dHex1
HexNAc5
NeuAc3

0.21

0.00

0.79

0.11

0.00

5.46

The percentages of total glycans of the indicated N-glycan species for UDP-3331, UDP-3331 + OFD1 rescue, UW172-4, and adult WT control fibroblasts samples are
shown along with reference (Ref ) low and high values derived from control samples. Species with values in the low-normal range in the JBTS10 sample(s) are flagged
with a pound sign (#). Species that are elevated above the normal range in JBTS10 sample(s) are flagged with a caret (^). Species below the normal range in JBTS10
sample(s) are flagged with a dagger (†)
#

Low normal in JBST10

^

Above normal in JBST10

†

Below normal in JBST10
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Fig. 4 Lectin staining for sialic acid epitopes in JBTS10 and control skin fibroblasts. a Lectin staining of α-2,6-sialic acid (SNA, green) and α-2,3-sialic
acid (MALII, blue) linkages in affected, rescued and control cells, as indicated. Arrows indicate atypical nuclear staining by SNA in UDP-3331. Scale
bars 20 µm. b Quantification of the fluorescence signal for SNA in nucleus relative to the entire cell for affected, rescued, and control cells under
paraformaldehyde fixation conditions. Error bars represent standard error. Single asterisks indicate p < 0.05; double asterisks indicate p < 0.001 relative
to both adult and pediatric male controls (unpaired, heteroscedastic t test). c Comparison of methanol and paraformaldehyde fixation on the rela‑
tive SNA staining intensity of the nucleus vs. the whole cell. Double asterisks indicate p < 0.001(unpaired, heteroscedastic t test). Error bars represent
standard error

Kane et al. Cilia (2017) 6:2

Page 14 of 18

Fig. 5 Nucleotide sugar analysis in JBTS10 and control skin fibroblasts. a Representative HPAEC trace for UDP-3331, UDP-3331 + OFD1 rescue, adult
WT, adult WT + OFD1 overexpression, pediatric male control cells, and 500 nM standard CMP-sialic acid. b Quantification of CMP-sialic acid levels in
affected and control cells (in μM) (single asterisks indicate p < 0.005 in an unpaired, heteroscedastic t test). Error bars represent standard error

(See figure on next page.)
Fig. 6 Neuraminidase treatment of adult WT primary cells. a Average cilia length of WT cells with and without neuraminidase (±Neuase) treat‑
ment to remove sialic acids from glycan chains; neuraminidase treatment significantly reduced average cilia length by ~1 µm. Error bars represent
standard error; p < 0.001 as determined in an unpaired, heteroscedastic t test. b The percentage of ciliated cells is decreased after neuraminidase
treatment; p < 0.05 as determined by a two-tailed Fisher’s Exact t test; error bars represent the 95% confidence interval for the binomial distribu‑
tion represent by the sample population. c, d Representative images of WT fibroblasts without (c) and with (d) neuraminidase treatment. Cilia are
stained with ARL13B antibody (red) and ɣ-tubulin (green). Scale bars 20 µm. e Lectin staining for sialic acid with SNA (green) and MAL II (white) and
galactose with PNA (red) in WT fibroblasts with DRAQ5 DNA counterstaining (blue). f Representative image of SNA (green) signal showing alpha
2,6-sialylation co-localizing with ARL13B-positive cilia (red) in WT cells without neuraminidase treatment. Scale bars 5 µm
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Conclusions
Our findings highlight a potential role for glycosylation
in contributing to pathogenesis of JBST10 and possibly
other ciliary disorders. The mechanism for the altered
glycosylation remains to be determined. Our observations raise the question as to whether glycosylation is
altered in other types of Joubert syndrome and more
severe ciliopathies. The impact of altered glycosylation in
contributing to pathophysiology in ciliopathies bears further study.
Additional files
Additional file 1: Table S1. O-glycan analysis results of UDP-3331
plasma.
Additional file 2: Figure S1. Overview of N- and O-linked glycosyla‑
tion pathways. N-linked glycosylation begins with the synthesis of the
dolichol phosphate-linked glycan precursor on the cytosolic face of the
endoplasmic reticulum (E.R.). Once the precursor molecule is flipped into
the E.R. lumen, it is further built up before being transferred to the nascent
polypeptide. After the glycosylated polypeptide is properly folded, it
is transferred to the cis Golgi where the high-37 mannose species are
trimmed and further matured by the addition N-acetylglucosamine
(GlcNAc), followed by galactose, fucose and, finally, sialic acid to form the
most prevalent, Complex N-linked glycans. An alternative pathway to gen‑
erate Hybrid glycan structures also exists. The enzymes that perform each
of these glycan-building steps are targeted to either cis, medial, or trans
Golgi stacks to facilitate proper assembly of the sugars. Two representative
O-linked glycosylation pathways are shown: O-GalNAc and O-mannose.
Much of the O-linked glycosylation reactions occur in the Golgi apparatus
and, similar to N-linked glycosylation, the complexity and length of
the sugars extends as the protein transits through the Golgi cisternae.
In JBTS10 patient samples, we observe a decrease in formation of the
mature, fully sialiylated N-glycans and alterations in levels of the O-linked
sialylated species. These species are shown in trans Golgi cisternae, which
has been highlighted in blue.
Additional file 3: Table S2. O-glycan analysis results of UDP-3331 and
UW172-4 primary dermal fibroblasts.
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